Market Research Logo

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2015

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2015’, provides an overview of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Overview
Therapeutics Development
Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Overview
Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Comparative Analysis
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics under Development by Companies
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics under Investigation by Universities/Institutes
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Products Glance
Early Stage Products
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Products under Development by Companies
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Products under Investigation by Universities/Institutes
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Companies Involved in Therapeutics Development
CEL-SCI Corporation
GeneCure LLC
Humabs BioMed SA
Kineta, Inc.
Myelo Therapeutics GmbH
Nanotherapeutics, Inc.
Novavax, Inc.
Phelix Therapeutics, LLC
Protein Sciences Corporation
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CEL-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D-3252 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FDX-000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IKT-014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LCA-60 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ML-188 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MMCatLMC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for SARS Virus Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myelo-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rOAS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SARS vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SARS vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SARS-CoV Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
severe acute respiratory syndrome vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
severe acute respiratory syndrome vaccine + middle east respiratory syndrome vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for SARS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Cathepsin L for SARS and Ebola Viral Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SSYA-10001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Target Spike Protein for SARS Infection - Drug Profile
Product Description
Mechanism of Action
R&D Progress
thiocarbazate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Recent Pipeline Updates
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Discontinued Products
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Product Development Milestones
Featured News & Press Releases
May 19, 2014: Kineta’s Novel Antiviral Drugs Show Encouraging Efficacy Against Dengue And SARS Viruses
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, H2 2015
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by CEL-SCI Corporation, H2 2015
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by GeneCure LLC, H2 2015
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Humabs BioMed SA, H2 2015
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Kineta, Inc., H2 2015
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Myelo Therapeutics GmbH, H2 2015
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Nanotherapeutics, Inc., H2 2015
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Novavax, Inc., H2 2015
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Phelix Therapeutics, LLC, H2 2015
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Protein Sciences Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Therapeutics - Recent Pipeline Updates, H2 2015
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects, H2 2015
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects (Contd..1), H2 2015
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, H2 2015
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report